Dr. Paul R. Fortin, MD, MPH, FRCPC holds the Tier 1 Canada Research Chair in Systemic Autoimmune Rheumatic Diseases, is Professor at Laval University, and Clinical Investigator at the CHU Research Center of Quebec – Laval University. He obtained his medical degree from Laval University and is a graduate of McGill University in rheumatology. He then obtained a Master’s in Public Health from Harvard University’s School of Public Health.

Dr. Fortin is working to better understand the bio-psycho-social impact of systemic autoimmune rheumatic diseases (SARD), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, inflammatory myositis, and antiphospholipid syndrome (APS). He is particularly interested in the development of interventions for the treatment of SLE, RA, and APS.

His methodological interests are the development and validation of diagnostic and prognostic tests, new treatments, and new ways to measure the impact of these treatments on the health status of the patient, and on the levels of activity or harm of the disease within SARDs. His other methodological interests include developing healthy lifestyle habits for people with SARD, and measuring the impact of patient knowledge.

Since 2011, Dr. Fortin has been working on the creation and establishment of a new computerized database and biobank that enables the collection of informative biospecimens and clinical data relevant to the study of SARDs. This biobank and database now has more than 13,000 biospecimens, from over 250 people, and has already contributed to translational and clinical research projects, as well as two projects funded by the Canadian Institutes of Health Research.

Dr. Fortin received the Canadian Rheumatology Association (CRA) Young Investigator Award in 1999, the Kirkland Scholar Award in 2008, and the prestigious Research Achievement Award from The Arthritis Society of Canada (2007- 2012). In 2010, he received the Lupus Ontario Hope Award for his outstanding leadership in improving the lives of people with lupus. In May 2015, he received the Jeffrey Shiroky Research Award for his clinical research achievements in rheumatology.

CHUL
2705, boulevard Laurier
T0-97
Québec, Québec
Canada G1V 4G2
389 entries « 37 of 39 »

Benk V, Ho V, Fortin PR, Zhang G, Levinton C, Freeman CR

Predictors of delay in starting radiation treatment for patients with early stage breast cancer

Journal Article

Int J Radiat Oncol Biol Phys, 41 (1), 1998.

Abstract | Links:

Ligier S, Fortin PR, Newkirk MM

A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE

Journal Article

Br J Rheumatol, 37 (12), 1998.

Abstract | Links:

Dobkin PL, Fortin PR, Joseph L, Esdaile JM, Danoff DS, Clarke AE

Psychosocial contributors to mental and physical health in patients with systemic lupus erythematosus

Journal Article

Arthritis Care Res, 11 (1), 1998.

Abstract | Links:

Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, Kalunian K, Nived O, Petri M, Sanchez-Guerrero J, Snaith M, Sturfelt G

The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus

Journal Article

Arthritis Rheum, 40 (5), 1997.

Abstract | Links:

Hudson N, Busque L, Rauch J, Kassis J, Fortin PR

Familial antiphospholipid syndrome and HLA-DRB gene associations

Journal Article

Arthritis Rheum, 40 (10), 1997.

| Links:

Mata S, Fortin PR, Fitzcharles MA, Starr MR, Joseph L, Watts CS, Gore B, Rosenberg E, Chhem RK, Esdaile JM

A controlled study of diffuse idiopathic skeletal hyperostosis. Clinical features and functional status

Journal Article

Medicine (Baltimore), 76 (2), 1997.

Abstract | Links:

Gladman D, Urowitz M, Fortin P, Isenberg D, Goldsmith C, Gordon C, Petri M

Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group

Journal Article

J Rheumatol, 23 (11), 1996.

| Links:

Moher D, Fortin P, Jadad AR, Juni P, Klassen T, Le Lorier J, Liberati A, Linde K, Penna A

Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews

Journal Article

Lancet, 347 (8998), 1996.

Abstract | Links:

Fortin PR

Vasculitides associated with malignancy

Journal Article

Curr Opin Rheumatol, 8 (1), 1996.

Abstract | Links:

Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus

Journal Article

Arthritis Rheum, 39 (3), 1996.

Abstract | Links:

389 entries « 37 of 39 »
Signaler des ajouts ou des modifications

Active projects

  • Canada research chair in Innovate Systemic Autoimmune Rheumatic Disease, from 2019-07-01 to 2026-06-30
  • FcgRI as a potential therapeutic target in inflammatory arthritis, from 2022-01-01 to 2025-03-31
  • Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, from 2020-04-01 to 2025-03-31
  • Risk stratification and personalized therapy in lupus pregnancies, from 2022-10-01 to 2027-09-30
  • Role of megakaryocytes in Systemic Lupus Erythematosus, from 2023-04-01 to 2028-03-31
  • Role of phosphatidylserine-specific phospholipase A1 (PLA1A) in the pathogenesis of rheumatic diseases, from 2023-01-01 to 2025-12-31

Recently finished projects

  • Booster dose of mRNA SARS-CoV-2 vaccine vs non mRNA vaccine for people living with systemic autoimmune rhumatic diseases without adequate humoral response post standard mRNA vaccination, from 2021-12-01 to 2022-11-30
  • CompreHensive Analysis of Mitochondria in Pathogenesis of SLE (CHAMPS), from 2021-09-01 to 2022-08-31
  • COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases / La réponse immunitaire au vaccin contre la COVID-19 chez des patients immunosupprimés en raison de maladies auto-immunes, from 2021-03-16 to 2023-03-31
  • Hydroxychloroquine in systemic lupus, from 2018-04-01 to 2023-03-31
  • Maladies Rhumatismales Autoimmunes Systémiques (MRAS) , from 2020-12-15 to 2023-03-31
  • Megakaryocyte: a new player in systemic lupus erythematosus, from 2022-09-01 to 2023-08-31
  • Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, from 2020-01-01 to 2022-12-31
  • Role of autotaxin bound to platelet-derived microparticles to development of vascular damage in arthritis., from 2015-07-01 to 2023-03-31
  • Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED) , from 2021-04-01 to 2023-09-30
  • The impact of antimalarial drugs in arthritis patients exposed to SARS-CoV-2- the CoVIRAL project, from 2020-04-01 to 2023-03-31
  • Understanding the pathogenesis of COVID-19, from 2020-03-01 to 2023-02-28
Data provided by the Université Laval research projects registery